{
  "fullName": "Vivek Subbiah",
  "slug": "vivek-subbiah",
  "title": "MD",
  "specialty": "Precision Oncology - Rare cancer trials",
  "geography": {
    "country": "India",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 110,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Andrea A. Hayes Dixon is an American surgeon. She was the first pediatric surgeon to perform a high-risk, life-saving procedure in children with a rare form of cancer and developed the first orthotropic xenograft model of metastatic Ewing's sarcoma. In 2002, she became the first African American female pediatric surgeon board-certified in the United States.",
  "aiSummary": "Vivek Subbiah is a precision oncology - rare cancer trials specialist with an H-index of 110 at MD Anderson (India-origin) (Faculty). Has been published in New England Journal of Medicine, The Lancet Oncology, Nature Medicine. Based in India.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Precision Oncology"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "MD Anderson (India-origin)",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Precision Oncology - Rare cancer trials"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations",
      "journal": "New England Journal of Medicine",
      "year": 2015,
      "citationCount": 1702,
      "doi": "10.1056/nejmoa1502309",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1502309",
      "verified": true
    },
    {
      "title": "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2017,
      "citationCount": 846,
      "doi": "10.1200/jco.2017.73.6785",
      "sourceUrl": "https://doi.org/10.1200/jco.2017.73.6785",
      "verified": true
    },
    {
      "title": "Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 808,
      "doi": "10.1056/nejmoa2005653",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2005653",
      "verified": true
    },
    {
      "title": "Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 728,
      "doi": "10.1056/nejmoa2005651",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2005651",
      "verified": true
    },
    {
      "title": "Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 489,
      "doi": "10.1016/s1470-2045(20)30321-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30321-1",
      "verified": true
    },
    {
      "title": "The next generation of evidence-based medicine",
      "journal": "Nature Medicine",
      "year": 2023,
      "citationCount": 486,
      "doi": "10.1038/s41591-022-02160-z",
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02160-z",
      "verified": true
    },
    {
      "title": "Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 432,
      "doi": "10.1016/s1470-2045(20)30068-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30068-1",
      "verified": true
    },
    {
      "title": "Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study",
      "journal": "The Lancet Oncology",
      "year": 2021,
      "citationCount": 425,
      "doi": "10.1016/s1470-2045(21)00247-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(21)00247-3",
      "verified": true
    },
    {
      "title": "Selective RET kinase inhibition for patients with RET-altered cancers",
      "journal": "Annals of Oncology",
      "year": 2018,
      "citationCount": 421,
      "doi": "10.1093/annonc/mdy137",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdy137",
      "verified": true
    },
    {
      "title": "Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis",
      "journal": "JAMA Oncology",
      "year": 2017,
      "citationCount": 395,
      "doi": "10.1001/jamaoncol.2017.5029",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2017.5029",
      "verified": true
    },
    {
      "title": "Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers",
      "journal": "Cancer Discovery",
      "year": 2018,
      "citationCount": 386,
      "doi": "10.1158/2159-8290.cd-18-0338",
      "sourceUrl": "https://doi.org/10.1158/2159-8290.cd-18-0338",
      "verified": true
    },
    {
      "title": "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial",
      "journal": "The Lancet Oncology",
      "year": 2022,
      "citationCount": 383,
      "doi": "10.1016/s1470-2045(22)00541-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(22)00541-1",
      "verified": true
    },
    {
      "title": "Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials",
      "journal": "Nature Medicine",
      "year": 2023,
      "citationCount": 333,
      "doi": "10.1038/s41591-022-02103-8",
      "sourceUrl": "https://doi.org/10.1038/s41591-022-02103-8",
      "verified": true
    },
    {
      "title": "Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers",
      "journal": "ESMO Open",
      "year": 2021,
      "citationCount": 332,
      "doi": "10.1016/j.esmoop.2021.100336",
      "sourceUrl": "https://doi.org/10.1016/j.esmoop.2021.100336",
      "verified": true
    },
    {
      "title": "Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study",
      "journal": "The Lancet Diabetes & Endocrinology",
      "year": 2021,
      "citationCount": 329,
      "doi": "10.1016/s2213-8587(21)00120-0",
      "sourceUrl": "https://doi.org/10.1016/s2213-8587(21)00120-0",
      "verified": true
    },
    {
      "title": "Clinical Development of BRAF plus MEK Inhibitor Combinations",
      "journal": "Trends in cancer",
      "year": 2020,
      "citationCount": 326,
      "doi": "10.1016/j.trecan.2020.05.009",
      "sourceUrl": "https://doi.org/10.1016/j.trecan.2020.05.009",
      "verified": true
    },
    {
      "title": "BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2018,
      "citationCount": 317,
      "doi": "10.1200/jco.2018.78.9990",
      "sourceUrl": "https://doi.org/10.1200/jco.2018.78.9990",
      "verified": true
    },
    {
      "title": "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study",
      "journal": "Annals of Oncology",
      "year": 2022,
      "citationCount": 314,
      "doi": "10.1016/j.annonc.2021.12.014",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2021.12.014",
      "verified": true
    },
    {
      "title": "Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells",
      "journal": "Clinical Cancer Research",
      "year": 2016,
      "citationCount": 309,
      "doi": "10.1158/1078-0432.ccr-16-1432",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-16-1432",
      "verified": true
    },
    {
      "title": "<i>RET</i> Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients",
      "journal": "Clinical Cancer Research",
      "year": 2016,
      "citationCount": 275,
      "doi": "10.1158/1078-0432.ccr-16-1679",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-16-1679",
      "verified": true
    },
    {
      "title": "RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies",
      "journal": "Journal of Thoracic Oncology",
      "year": 2020,
      "citationCount": 271,
      "doi": "10.1016/j.jtho.2020.01.006",
      "sourceUrl": "https://doi.org/10.1016/j.jtho.2020.01.006",
      "verified": true
    },
    {
      "title": "Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial",
      "journal": "Nature Medicine",
      "year": 2023,
      "citationCount": 249,
      "doi": "10.1038/s41591-023-02321-8",
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02321-8",
      "verified": true
    },
    {
      "title": "State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers",
      "journal": "Journal of Clinical Oncology",
      "year": 2020,
      "citationCount": 243,
      "doi": "10.1200/jco.19.02551",
      "sourceUrl": "https://doi.org/10.1200/jco.19.02551",
      "verified": true
    },
    {
      "title": "The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians",
      "journal": "Annals of Oncology",
      "year": 2020,
      "citationCount": 242,
      "doi": "10.1016/j.annonc.2020.07.002",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2020.07.002",
      "verified": true
    },
    {
      "title": "Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations",
      "journal": "Annals of Oncology",
      "year": 2020,
      "citationCount": 234,
      "doi": "10.1016/j.annonc.2020.10.599",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2020.10.599",
      "verified": true
    },
    {
      "title": "Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study",
      "journal": "Cancer Research",
      "year": 2016,
      "citationCount": 231,
      "doi": "10.1158/0008-5472.can-15-3043",
      "sourceUrl": "https://doi.org/10.1158/0008-5472.can-15-3043",
      "verified": true
    },
    {
      "title": "Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial",
      "journal": "Nature Medicine",
      "year": 2022,
      "citationCount": 221,
      "doi": "10.1038/s41591-022-01931-y",
      "sourceUrl": "https://doi.org/10.1038/s41591-022-01931-y",
      "verified": true
    },
    {
      "title": "Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation",
      "journal": "Cancer Discovery",
      "year": 2016,
      "citationCount": 213,
      "doi": "10.1158/2159-8290.cd-16-0050",
      "sourceUrl": "https://doi.org/10.1158/2159-8290.cd-16-0050",
      "verified": true
    },
    {
      "title": "Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol",
      "journal": "Annals of Oncology",
      "year": 2016,
      "citationCount": 198,
      "doi": "10.1093/annonc/mdw018",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdw018",
      "verified": true
    },
    {
      "title": "EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment",
      "journal": "Nature Reviews Clinical Oncology",
      "year": 2021,
      "citationCount": 190,
      "doi": "10.1038/s41571-021-00558-1",
      "sourceUrl": "https://doi.org/10.1038/s41571-021-00558-1",
      "verified": true
    },
    {
      "title": "FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies",
      "journal": "Annals of Oncology",
      "year": 2022,
      "citationCount": 188,
      "doi": "10.1016/j.annonc.2022.02.001",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2022.02.001",
      "verified": true
    },
    {
      "title": "Selpercatinib in Patients With <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2022,
      "citationCount": 185,
      "doi": "10.1200/jco.22.00393",
      "sourceUrl": "https://doi.org/10.1200/jco.22.00393",
      "verified": true
    },
    {
      "title": "Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer",
      "journal": "JAMA Oncology",
      "year": 2016,
      "citationCount": 185,
      "doi": "10.1001/jamaoncol.2016.5281",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2016.5281",
      "verified": true
    },
    {
      "title": "Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience",
      "journal": "Investigational New Drugs",
      "year": 2017,
      "citationCount": 182,
      "doi": "10.1007/s10637-017-0534-0",
      "sourceUrl": "https://doi.org/10.1007/s10637-017-0534-0",
      "verified": true
    },
    {
      "title": "Of mice and men: divergent risks of teriparatide-induced osteosarcoma",
      "journal": "Osteoporosis International",
      "year": 2009,
      "citationCount": 176,
      "doi": "10.1007/s00198-009-1004-0",
      "sourceUrl": "https://doi.org/10.1007/s00198-009-1004-0",
      "verified": true
    },
    {
      "title": "Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial",
      "journal": "Annals of Oncology",
      "year": 2022,
      "citationCount": 165,
      "doi": "10.1016/j.annonc.2022.08.002",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2022.08.002",
      "verified": true
    },
    {
      "title": "Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges",
      "journal": "Nature Reviews Clinical Oncology",
      "year": 2023,
      "citationCount": 165,
      "doi": "10.1038/s41571-023-00794-7",
      "sourceUrl": "https://doi.org/10.1038/s41571-023-00794-7",
      "verified": true
    },
    {
      "title": "Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers",
      "journal": "Clinical Cancer Research",
      "year": 2017,
      "citationCount": 158,
      "doi": "10.1158/1078-0432.ccr-17-2007",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-17-2007",
      "verified": true
    },
    {
      "title": "Precision therapy for RET-altered cancers with RET inhibitors",
      "journal": "Trends in cancer",
      "year": 2021,
      "citationCount": 158,
      "doi": "10.1016/j.trecan.2021.07.003",
      "sourceUrl": "https://doi.org/10.1016/j.trecan.2021.07.003",
      "verified": true
    },
    {
      "title": "Ewing’s Sarcoma: Standard and Experimental Treatment Options",
      "journal": "Current Treatment Options in Oncology",
      "year": 2009,
      "citationCount": 151,
      "doi": "10.1007/s11864-009-0104-6",
      "sourceUrl": "https://doi.org/10.1007/s11864-009-0104-6",
      "verified": true
    },
    {
      "title": "Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification",
      "journal": "Annals of Oncology",
      "year": 2018,
      "citationCount": 151,
      "doi": "10.1093/annonc/mdy119",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdy119",
      "verified": true
    },
    {
      "title": "Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma",
      "journal": "Journal for ImmunoTherapy of Cancer",
      "year": 2019,
      "citationCount": 149,
      "doi": "10.1186/s40425-019-0722-x",
      "sourceUrl": "https://doi.org/10.1186/s40425-019-0722-x",
      "verified": true
    },
    {
      "title": "Advances in Targeting RET-Dependent Cancers",
      "journal": "Cancer Discovery",
      "year": 2020,
      "citationCount": 147,
      "doi": "10.1158/2159-8290.cd-19-1116",
      "sourceUrl": "https://doi.org/10.1158/2159-8290.cd-19-1116",
      "verified": true
    },
    {
      "title": "Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials",
      "journal": "Journal for ImmunoTherapy of Cancer",
      "year": 2017,
      "citationCount": 142,
      "doi": "10.1186/s40425-017-0301-y",
      "sourceUrl": "https://doi.org/10.1186/s40425-017-0301-y",
      "verified": true
    },
    {
      "title": "Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses",
      "journal": "Cancer Immunology Research",
      "year": 2019,
      "citationCount": 140,
      "doi": "10.1158/2326-6066.cir-18-0793",
      "sourceUrl": "https://doi.org/10.1158/2326-6066.cir-18-0793",
      "verified": true
    },
    {
      "title": "COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials",
      "journal": "Nature Reviews Clinical Oncology",
      "year": 2021,
      "citationCount": 139,
      "doi": "10.1038/s41571-021-00487-z",
      "sourceUrl": "https://doi.org/10.1038/s41571-021-00487-z",
      "verified": true
    },
    {
      "title": "Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?",
      "journal": "Trends in cancer",
      "year": 2020,
      "citationCount": 135,
      "doi": "10.1016/j.trecan.2020.01.005",
      "sourceUrl": "https://doi.org/10.1016/j.trecan.2020.01.005",
      "verified": true
    },
    {
      "title": "Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial",
      "journal": "Clinical Cancer Research",
      "year": 2021,
      "citationCount": 132,
      "doi": "10.1158/1078-0432.ccr-21-0800",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-21-0800",
      "verified": true
    },
    {
      "title": "Drugging KRAS: current perspectives and state-of-art review",
      "journal": "Journal of Hematology & Oncology",
      "year": 2022,
      "citationCount": 131,
      "doi": "10.1186/s13045-022-01375-4",
      "sourceUrl": "https://doi.org/10.1186/s13045-022-01375-4",
      "verified": true
    },
    {
      "title": "Phase 2 study of pembrolizumab in patients with advanced rare cancers",
      "journal": "Journal for ImmunoTherapy of Cancer",
      "year": 2020,
      "citationCount": 126,
      "doi": "10.1136/jitc-2019-000347",
      "sourceUrl": "https://doi.org/10.1136/jitc-2019-000347",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:17.000Z",
  "openalexId": "https://openalex.org/A5043675371"
}